Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study

Colorectal cancers are one of the most prevalent tumour types worldwide and, despite the emergence of targeted and biologic therapies, have among the highest mortality rates. The Personalized OncoGenomics (POG) program at BC Cancer performs whole genome and transcriptome analysis (WGTA) to identify specific alterations in an individual’s cancer that may be most effectively targeted. Informed using WGTA, a patient with advanced mismatch repair-deficient colorectal cancer was treated with the antihypertensive drug irbesartan and experienced a profound and durable response. We describe the subsequent relapse of this patient and potential mechanisms of response using WGTA and multiplex immunohistochemistry (m-IHC) profiling of biopsies before and after treatment from the same metastatic site of the L3 spine. We did not observe marked differences in the genomic landscape before and after treatment. Analyses revealed an increase in immune signalling and infiltrating immune cells, particularly CD8+ T cells, in the relapsed tumour. These results indicate that the observed anti-tumour response to irbesartan may have been due to an activated immune response. Determining whether there may be other cancer contexts in which irbesartan may be similarly valuable will require additional studies.

[1]  D. Lin,et al.  Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden , 2023, JAMA network open.

[2]  E. Pleasance,et al.  TMBur: a distributable tumor mutation burden approach for whole genome sequencing , 2022, BMC Medical Genomics.

[3]  B. Nelson,et al.  Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities , 2022, Nature Reviews Cancer.

[4]  H. Guirgis.  Costs of Extended Use of the Immune Checkpoint Inhibitors in First-line Non-Small Cell Lung Cancer , 2021, Journal of Clincal Pathways.

[5]  Jennifer S. Lin,et al.  Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. , 2021, JAMA.

[6]  Anna Danielewicz,et al.  A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis , 2021, Cancers.

[7]  Steven J. M. Jones,et al.  Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors , 2020, Clinical Cancer Research.

[8]  T. Chan,et al.  The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Steven J. M. Jones,et al.  Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes , 2020, Nature Cancer.

[10]  E. Pleasance,et al.  Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant , 2019, Cold Spring Harbor molecular case studies.

[11]  Steven J. M. Jones,et al.  NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma , 2019, Clinical Cancer Research.

[12]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[13]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[14]  Steven J. M. Jones,et al.  Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making , 2018, Cold Spring Harbor molecular case studies.

[15]  Andrew K. Sewell,et al.  VDJdb: a curated database of T-cell receptor sequences with known antigen specificity , 2017, Nucleic Acids Res..

[16]  F. Ciardiello,et al.  Present and future of metastatic colorectal cancer treatment: A review of new candidate targets , 2017, World journal of gastroenterology.

[17]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[18]  The Gene Ontology Consortium,et al.  Expansion of the Gene Ontology knowledgebase and resources , 2016, Nucleic Acids Res..

[19]  Richard A. Moore,et al.  Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Gwendolyn M. Jang,et al.  Meta- and Orthogonal Integration of Influenza "OMICs" Data Defines a Role for UBR4 in Virus Budding. , 2015, Cell host & microbe.

[21]  Mikhail Pogorelyy,et al.  VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires , 2015, PLoS Comput. Biol..

[22]  L. Wu,et al.  Irbesartan attenuates TNF-α-induced ICAM-1, VCAM-1, and E-selectin expression through suppression of NF-κB pathway in HUVECs. , 2015, European review for medical and pharmacological sciences.

[23]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[24]  E. Komech,et al.  tcR: an R package for T cell receptor repertoire advanced data analysis , 2015, BMC Bioinformatics.

[25]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[26]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[27]  Steven J. M. Jones,et al.  JAGuaR: Junction Alignments to Genome for RNA-Seq Reads , 2014, PloS one.

[28]  A. Bouchard-Côté,et al.  PyClone: statistical inference of clonal population structure in cancer , 2014, Nature Methods.

[29]  Jose M Garcia,et al.  Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer. , 2013, Translational oncology.

[30]  Li-sheng Liu,et al.  A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists , 2013, Pharmacological Reviews.

[31]  Victor Appay,et al.  A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. , 2013, Immunity.

[32]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[33]  A. Bashashati,et al.  Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer , 2012, Genome research.

[34]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[35]  Gholamreza Haffari,et al.  Feature-based classifiers for somatic mutation detection in tumour–normal paired sequencing data , 2011, Bioinform..

[36]  Steven J. M. Jones,et al.  Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors , 2010, Genome Biology.

[37]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[38]  U. Kintscher,et al.  Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. , 2005, Diabetes.

[39]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[40]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[41]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[42]  E. Wagner,et al.  AP-1: a double-edged sword in tumorigenesis , 2003, Nature Reviews Cancer.